Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;1(4):342-354.
doi: 10.1007/s13238-010-0054-6. Epub 2010 May 8.

Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines

Shibo Jiang  1   2 , Runming Li  3 , Lanying Du  4 , Shuwen Liu  5
Affiliations
Review

Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines

Shibo Jiang et al. Protein Cell. 2010 Apr.

Abstract

Seasonal influenza epidemics and influenza pandemics caused by influenza A virus (IAV) has resulted in millions of deaths in the world. The development of anti-IAV vaccines and therapeutics is urgently needed for prevention and treatment of IAV infection and for controlling future influenza pandemics. Hemagglutinin (HA) of IAV plays a critical role in viral binding, fusion and entry, and contains the major neutralizing epitopes. Therefore, HA is an attractive target for developing anti-IAV drugs and vaccines. Here we have reviewed the recent progress in study of conformational changes of HA during viral fusion process and development of HA-based antiviral therapeutics and vaccines.

PubMed Disclaimer

References

    1. Amorij J.P., Meulenaar J., Hinrichs W.L., Stegmann T., Huckriede A., Coenen F., Frijlink H.W. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine. 2007;25:6447–6457. doi: 10.1016/j.vaccine.2007.06.054. - DOI - PubMed
    1. Barefoot B.E., Athearn K., Sample C.J., Ramsburg E.A. Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge. Vaccine. 2009;28:79–89. doi: 10.1016/j.vaccine.2009.09.112. - DOI - PMC - PubMed
    1. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J. C., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004;172:6290–6297. doi: 10.4049/jimmunol.172.10.6290. - DOI - PubMed
    1. Beppu Y., Imamura Y., Tashiro M., Towatari T., Ariga H., Kido H. Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses. J Biochem. 1997;121:309–316. doi: 10.1093/oxfordjournals.jbchem.a021588. - DOI - PubMed
    1. Biesova Z., Miller M.A., Schneerson R., Shiloach J., Green K.Y., Robbins J.B., Keith J.M. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine. 2009;27:6234–6238. doi: 10.1016/j.vaccine.2009.07.107. - DOI - PMC - PubMed

Publication types